NCT00369473已完成2 期
A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 690
- 主要终点
- To assess long-term safety of AMG 108 SC in subjects with RA previously enrolled in study 20050168
研究概览
简要总结
The purpose of this study is to assess long-term safety of SC AMG 108 in the treatment of RA
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll.
排除标准
- •Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.
研究组 & 干预措施
1
Experimental
350
干预措施: AMG 108 (Drug)
2
Experimental
350
干预措施: AMG 108 (Drug)
结局指标
主要结局
To assess long-term safety of AMG 108 SC in subjects with RA previously enrolled in study 20050168
时间窗: 144 Weeks
次要结局
- To determine whether long-term use of AMG 108 improves function in subjects with RA(144 Weeks)
研究者
相似试验
Unknown
不适用
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than RisperidoneSchizophrenia, CatatonicSchizophrenia, DisorganizedSchizophrenia, ParanoidPsychotic DisordersSchizophreniaNCT00563017Hospital Authority, Hong Kong30
已完成
2 期
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisRelapsing Multiple SclerosisNCT03996291Sanofi125
Unknown
不适用
Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone GraftAnkle and Hindfoot ArthrodesisNCT02879149BioMimetic Therapeutics150
Unknown
不适用
Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone GraftAnkle and Hindfoot ArthrodesisNCT03998137BioMimetic Therapeutics94
已完成
3 期
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)Peanut AllergyNCT03292484Aimmune Therapeutics, Inc.911